18 Qian Z, Haessler M, Lemos JA, Arsenault JR, Aguirre JE, Gilbert JR, et al. Targeting vascular injury using Hantavirus-pseudotyped lentiviral vectors. Molec Ther. 2006;13:694–704. Ralph GS, Bienemann A, Harding TC, Hopton M, Henley J, Uney JB. Targeting of tetracycline-regulatable transgene expres- sion specifically to neuronal and glial cell populations using adenoviral vectors. NeuroReport. 2000;11: 2051–5. Rea D, Havenga MJ, van Den AM, Sutmuller RP, Lemckert A, Hoeben RC, et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber- modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol. 2001;166:5236–44. Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci USA. 1996;93:15266–71. Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balyasnikova IV, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol. 2001;19: 838–42. Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 1993;12:2099–108. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol. 1998;72:7909–15. Russell WC. Update on adenovirus and its vectors. J Gen Virol. 2000;81:2573–604. Saenz DT, Poeschla EM. FIV: from lentivirus to lentivector. J Gene Med. 2004;6(Suppl 1):S95–104. Sailaja G, HogenEsch H, North A, Hays J, Mittal SK. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune re- sponse. Gene Ther. 2002;9:1722–9. Sakurai F, Kawabata K, Koizumi N, Inoue N, Okabe M, Yamaguchi T, et al. Adenovirus serotype 35 vector- mediated transduction into human CD46-transgenic mice. Gene Ther. 2006;13:1118–26. Salone B, Martina Y, Piersanti S, Cundari E, Cherubini G, Franqueville L, et al. Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5. J Virol. 2003;77:13448–54. Sanders DA. Ebola virus glycoproteins: guidance devices for targeting gene therapy vectors. Expert Opin Biol Ther. 2004;4:329–36. Schaack J, Bennett ML, Colbert JD, Torres AV, Clayton GH, Ornelles D, et al. E1A and E1B proteins inhibit inflam- mation induced by adenovirus. Proc Natl Acad Sci USA. 2004;101:3124–9. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expres- sion and decreased toxicity. Nat Genet. 1998;18:180–3. Schiedner G, Hertel S, Johnston M, Biermann V, Dries V, Kochanek S. Variables affecting in vivo performance of Cell Biol Toxicol (2010) 26:1–20 high-capacity adenovirus vectors. J Virol. 2002;76: 1600–9. Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes iso- lated from human tissues. J Virol. 2005;79:14793–803. Segerman A, Arnberg N, Erikson A, Lindman K, Wadell G. There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J Virol. 2003a;77:1157–62. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 2003b;77:9183–91. Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res. 2009;143:184–94. Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S. Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol. 2005;90:53–9. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell- surface receptors. Hum Gene Ther. 2001;12:1697–711. Shimada T, Fujii H, Mitsuya H, Nienhuis AW. Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest. 1991;88:1043–7. Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, Curiel DT. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology. 2004;322:349–59. Sims K, Ahmed Z, Gonzalez AM, Read ML, Cooper-Charles L, Berry M, et al. Targeting adenoviral transgene expres- sion to neurons. Mol Cell Neurosci. 2008;39:411–7. Sinn PL, Burnight ER, Shen H, Fan H, McCray PB Jr. Inclusion of Jaagsiekte sheep retrovirus proviral elements markedly increases lentivirus vector pseudotyping effi- ciency. Molec Ther. 2005;11:460–9. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet. 2000;1:91–9. Song JJ, Lee B, Chang JW, Kim JH, Kwon YK, Lee H. Optimization of vesicular stomatitis virus-G pseudotyped feline immunodeficiency virus vector for minimized cytotoxicity with efficient gene transfer. Virus Res. 2003; 93:25–30. Spergel JM, Chen-Kiang S. Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proc Natl Acad Sci USA. 1991;88:6472–6. Spergel JM, Hsu W, Akira S, Thimmappaya B, Kishimoto T, Chen-Kiang S. NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A. J Virol. 1992;66:1021–30. Staal FJ, Pike-Overzet K, Ng YY, van Dongen JJ. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? Leukemia. 2008;22:1849– 52. Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 2000;7:13–9.